Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up

Vaccine-induced immunity wanes over time and warrants booster doses. We investigated the long-term (32 weeks) immunogenicity and safety of a third, homologous, open-label booster dose of TURKOVAC, administered 12 weeks after completion of the primary series in a randomized, controlled, double-blind,...

Descripción completa

Detalles Bibliográficos

Autores principales:	Zafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, Hazel Yetiskin, Busra Kaplan, Muhammet Ali Uygut, Ahmet Furkan Aslan, Adnan Bayram, Mumtaz Mazicioglu, Gamze Kalin Unuvar, Zeynep Ture Yuce, Gunsu Aydin, Refika Kamuran Kaya, Ihsan Ates, Ates Kara, Aykut Ozdarendeli
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2024-01-01
Colección:	Vaccines
Materias:	booster COVID-19 immunogenicity inactivated vaccine neutralizing antibody S1 RBD
Acceso en línea:	https://www.mdpi.com/2076-393X/12/2/140
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!